Prebiotic-Engineered Oral Nanoplatform against Ulcerative Colitis via Photodynamic Remodeling of Gut Microbiota and Macrophage Polarization

Ulcerative colitis (UC), a chronic inflammatory bowel disease characterized by recurrent colonic mucosal inflammation, substantially impairs patient quality of life. While photodynamic therapy offers promise for UC treatment, conventional photosensitizers face limitations including poor solubility and inadequate targeting. Here, we developed an orally administered multifunctional nanosystem (CBF@LCP) to remodel dysbiotic gut microbiota and enable synergistic phototherapy. The core comprises reactive-oxygen-species-responsive liposomes, encapsulating our previously established iodinated cyanine photosensitizer CyI, and folic acid with bovine serum albumin via amide bonds (CBF@L). This outer layer is coated with a prebiotic chitosan/pectin shell via layer-by-layer assembly. Following oral administration, CBF@LCP withstands the gastrointestinal tract via pH-dependent contraction. Following gastrointestinal-enzyme-mediated decoating, the exposed CBF@L is internalized by folate-receptor-overexpressing M1 macrophages at colitis sites. Under near-infrared irradiation, CyI executes dual photodynamic therapy/photothermal therapy, ablating pro-inflammatory macrophages while exploiting the oxygen-augmented UC microenvironment to enhance reactive oxygen species generation without exogenous oxygen carriers. Concurrently, the prebiotic shell restores microbial eubiosis by suppressing pathogens and promoting beneficial bacteria. In vivo studies in dextran sulfate sodium-induced colitis models demonstrate that CBF@LCP achieves targeted drug release, mitigates inflammation, reprograms macrophage polarization, preserves intestinal barrier integrity, and activates the phosphatidylinositol 3-kinase/AKT signaling pathway. Gut microbiota and transcriptomic analyses confirm restoration of microbial balance and mucosal healing. This work presents a potent targeted strategy for UC management through microbiota remodeling and oxygen-enhanced phototherapy.

Authors

Institutions

Publication Details

Journal
Biomaterials Research
Published
2025-01-01
DOI
https://doi.org/10.34133/bmr.0283
Citations
1
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prebiotic-Engineered Oral Nanoplatform against Ulcerative Colitis via Photodynamic Remodeling of Gut Microbiota and Macrophage Polarization

Yifan Zhao, Jie Cao, Geun-soo Kim, Shangyong Li et al.
1 citations
Biomaterials Research
Nanoplatforms for cancer theranostics
0.67
article

Prebiotic-Engineered Oral Nanoplatform against Ulcerative Colitis via Photodynamic Remodeling of Gut Microbiota and Macrophage Polarization

Yifan Zhao, Jie Cao, Geun-soo Kim, Shangyong Li, Peng Liu, Tong Dai, Ningning He, Zequn Li, Huimei Jiang
article en
1 citations

Abstract

Ulcerative colitis (UC), a chronic inflammatory bowel disease characterized by recurrent colonic mucosal inflammation, substantially impairs patient quality of life. While photodynamic therapy offers promise for UC treatment, conventional photosensitizers face limitations including poor solubility and inadequate targeting. Here, we developed an orally administered multifunctional nanosystem (CBF@LCP) to remodel dysbiotic gut microbiota and enable synergistic phototherapy. The core comprises reactive-oxygen-species-responsive liposomes, encapsulating our previously established iodinated cyanine photosensitizer CyI, and folic acid with bovine serum albumin via amide bonds (CBF@L). This outer layer is coated with a prebiotic chitosan/pectin shell via layer-by-layer assembly. Following oral administration, CBF@LCP withstands the gastrointestinal tract via pH-dependent contraction. Following gastrointestinal-enzyme-mediated decoating, the exposed CBF@L is internalized by folate-receptor-overexpressing M1 macrophages at colitis sites. Under near-infrared irradiation, CyI executes dual photodynamic therapy/photothermal therapy, ablating pro-inflammatory macrophages while exploiting the oxygen-augmented UC microenvironment to enhance reactive oxygen species generation without exogenous oxygen carriers. Concurrently, the prebiotic shell restores microbial eubiosis by suppressing pathogens and promoting beneficial bacteria. In vivo studies in dextran sulfate sodium-induced colitis models demonstrate that CBF@LCP achieves targeted drug release, mitigates inflammation, reprograms macrophage polarization, preserves intestinal barrier integrity, and activates the phosphatidylinositol 3-kinase/AKT signaling pathway. Gut microbiota and transcriptomic analyses confirm restoration of microbial balance and mucosal healing. This work presents a potent targeted strategy for UC management through microbiota remodeling and oxygen-enhanced phototherapy.

Biomaterials ResearchVol. 29
Qingdao University (CN), Vanderbilt University (US), Affiliated Hospital of Qingdao University (CN)
Openalex Percentile: Top 25%
Nanoplatforms for cancer theranostics
0.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.